Nitric Oxide Synthases Activation and Inhibition by Metallacarborane-Cluster-Based Isoform-Specific Affectors

被引:15
作者
Kaplanek, Robert [1 ]
Martasek, Pavel [2 ,3 ]
Gruener, Bohumir [4 ]
Panda, Satya [5 ]
Rak, Jakub [1 ]
Masters, Bettie Sue Siler [5 ]
Kral, Vladimir [1 ,6 ]
Roman, Linda J. [5 ]
机构
[1] Inst Chem Technol, Dept Analyt Chem, CR-16628 Prague 6, Czech Republic
[2] Charles Univ Prague, Fac Med 1, Prague 12108 2, Czech Republic
[3] Univ Gen Hosp, Prague 12808 2, Czech Republic
[4] Acad Sci Czech Republ, Inst Inorgan Chem, Area Res Inst, Husinec 25068, Rez U Prahy, Czech Republic
[5] Univ Texas Hlth Sci Ctr San Antonio, Dept Biochem, San Antonio, TX 78229 USA
[6] Zentiva R&D, Prague 10237 10, Czech Republic
关键词
HIGHLY SELECTIVE INHIBITORS; DICARBA-CLOSO-DODECABORANE; AMIDE BOND PEPTIDOMIMETICS; NEUTRON-CAPTURE THERAPY; ELECTRON FLOW-THROUGH; N-OMEGA-NITROARGININE; MEDICINAL CHEMISTRY; DIPEPTIDE AMIDES; BORON CLUSTERS; DRUG DISCOVERY;
D O I
10.1021/jm300805x
中图分类号
R914 [药物化学];
学科分类号
100701 ;
摘要
A small-library of boron-cluster- and metallacarborane-cluster-based ligands was designed, prepared, and tested for isoform-selective activation or inhibition of the three nitric oxide synthase isoforms. On the basis of the concept of creating a hydrophobic analogue of a natural substrate, a stable and nontoxic basic boron cluster system, previously used for boron neutron capture therapy, was modified by the addition of positively charged moieties to its periphery, providing hydrophobic and nonclassical hydrogen, bonding interactions with the protein. Several of these compounds show efficacy for Inhibition of NO synthesis with differential effects on the various nitric oxide synthase isoforms.
引用
收藏
页码:9541 / 9548
页数:8
相关论文
共 77 条
  • [1] Nitric oxide synthases: structure, function and inhibition
    Alderton, WK
    Cooper, CE
    Knowles, RG
    [J]. BIOCHEMICAL JOURNAL, 2001, 357 (03) : 593 - 615
  • [2] Enzymatic function of nitric oxide synthases
    Andrew, PJ
    Mayer, B
    [J]. CARDIOVASCULAR RESEARCH, 1999, 43 (03) : 521 - 531
  • [3] The bioinorganic and medicinal chemistry of carboranes: from new drug discovery to molecular imaging and therapy
    Armstrong, Andrea F.
    Valliant, John F.
    [J]. DALTON TRANSACTIONS, 2007, (38) : 4240 - 4251
  • [4] Bregadze V. I., 2006, Anti-Cancer Agents in Medicinal Chemistry, V6, P75, DOI 10.2174/187152006776119180
  • [5] Bruckdorfer Richard, 2005, Molecular Aspects of Medicine, V26, P3, DOI 10.1016/j.mam.2004.09.002
  • [6] From nonpeptide toward noncarbon protease inhibitors:: Metallacarboranes as specific and potent inhibitors of HIV protease
    Cígler, P
    Kozísek, M
    Rezácová, P
    Brynda, J
    Otwinowski, Z
    Pokorná, J
    Plesek, J
    Grüner, B
    Dolecková-Maresová, L
    Mása, M
    Sedlácek, J
    Bodem, J
    Kräusslich, HG
    Král, V
    Konvalinka, J
    [J]. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2005, 102 (43) : 15394 - 15399
  • [7] Connors K. A., 1981, BINDING CONSTANTS
  • [8] Structure of nitric oxide synthase oxygenase dimer with pterin and substrate
    Crane, BR
    Arvai, AS
    Ghosh, DK
    Wu, CQ
    Getzoff, ED
    Stuehr, DJ
    Tainer, JA
    [J]. SCIENCE, 1998, 279 (5359) : 2121 - 2126
  • [9] Boronated DNA-binding compounds as potential agents for boron neutron capture therapy
    Crossley, Ellen L.
    Ziolkowski, Erin J.
    Coderre, Jeffrey A.
    Rendina, Louis M.
    [J]. MINI-REVIEWS IN MEDICINAL CHEMISTRY, 2007, 7 (03) : 303 - 313
  • [10] Protein kinase C modulators bearing dicarba-closo-dodecaborane as a hydrophobic pharmacophore
    Endo, Y
    Yoshimi, T
    Kimura, K
    Itai, A
    [J]. BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, 1999, 9 (17) : 2561 - 2564